The role of bone‐modifying agents in myeloma bone disease
ABSTRACT Bone disease is common in patients with multiple myeloma (MM), which manifests as bone pain and skeletal‐related events (SREs) such as pathological fractures and spinal cord compression. Myeloma bone disease (MBD) can adversely affect the quality of life of patients and have negative effect...
Main Authors: | Huifang Lu, Xerxes Pundole, Hans C. Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | JBMR Plus |
Subjects: | |
Online Access: | https://doi.org/10.1002/jbm4.10518 |
Similar Items
-
Petunidin, a B-ring 5′-<i>O</i>-Methylated Derivative of Delphinidin, Stimulates Osteoblastogenesis and Reduces sRANKL-Induced Bone Loss
by: Masahiro Nagaoka, et al.
Published: (2019-06-01) -
The Osteoclast in Bone Metastasis: Player and Target
by: Antonio Maurizi, et al.
Published: (2018-06-01) -
Advances and Unmet Needs in the Therapeutics of Bone Fragility
by: Sabashini K. Ramchand, et al.
Published: (2018-09-01) -
Myeloma Bone Disease: The Osteoblast in the Spotlight
by: Rebecca E. Andrews, et al.
Published: (2021-09-01) -
Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities
by: Niall M Byrne, et al.
Published: (2019-03-01)